Design and baseline characteristics of the LANDMARK study

Conclusions The LANDMARK study will determine whether LC, a non-Ca-based P binder, reduces cardiovascular mortality and morbidity in chronic hemodialysis patients.

http://link.springer.com/10.1007/s10157-016-1310-8

Source: Clinical and Experimental Nephrology - July 11, 2016 Category: Urology & Nephrology Source Type: research